企业办公
搜索
culture

专业制药75年

culture

Guolong Pharmaceutical

culture

Guolong Pharmaceutical

Guolong Pharmaceutical

It is a wholly-owned subsidiary of Shijiazhuang No.4 Pharmaceutical Group (SSY Group), which is a professional API manufacturer established and developed by the group to actively promote the development strategy of "API + preparation", make full use of the advantages of the whole industry chain, adhere to the concept of "green pharmaceutical", introduce advanced equipment and green technology at home and abroad, It mainly produces bulk API azithromycin and its intermediates, hydroxyethyl starch series such as hydroxyethyl starch 40 and hydroxyethyl starch 130/0.4, moxifloxacin hydrochloride, arbidol hydrochloride, bromhexine hydrochloride and other characteristic API products.

  • icon

    124913.3

    Covering an area of 124913.3 square meters

  • icon

    30

    +

    More than 30 kinds of bulk APIs and specialty APIs

Adhering to the innovative idea of "combining imitation and innovation", we continue to increase investment in new product research and development, and create high-end innovation platforms relying on Hebei Enterprise Technology Center, Hebei Technology Innovation Center, and postdoctoral research workstations. Actively promoting the integrated innovation of production process, through over-coming key technologies such as API synthesis, we are able to develop a more refined, serialized and high-end high-value added APIs and innovative API products, so as to create a competitive advantage in variety building. 

Guolong Pharmaceutical
00:00:18
Guolong Pharmaceutical
Time of issue:
2024/06/20

Creation of domestic bulk pharmaceutical innovation highland

Develop refined, serialized, and high-end bulk pharmaceutical intermediates and innovative bulk pharmaceutical intermediates with high added value to build variety competition advantages.

PRODUCTS

 新闻中心

“小巨人”城市画像—— 河北沧州:锚定专精特新 助推“小巨人”动能迸发

11/13/2022

目前,河北广祥制药有限公司已经开启了争创国家级专精特新“小巨人”企业之路,他们已瞄准市场空白,准备深耕特色原料药领域,借助国家、省、市支持生物医药产业发展的一系列政策举措,持续加大科研投入,不断推动企业发展迈上台阶、实现新跨越。
See more information

点赞!石家庄四药集团广祥制药“00后”员工吕晓龙成功捐献造血干细胞

03/13/2023

2月27日上午,在河北医科大学第三医院造血干细胞采集室里,经过5个多小时的采集,一位“00后”小伙儿成功捐献了395毫升造血干细胞悬液,这些将被送去远方的“生命种子”,寄托着深沉的爱与重获生机的希望。这位“00后”小伙儿就是来自石家庄四药集团河北广祥制药有限公司仓储服务部的吕晓龙。他也是这家集团第二位成功捐献造血干细胞的员工。
See more information

石四药加快原料药高质量发展 向原料药强企迈进

05/23/2022

在贯彻国家新发展理念和实现制药大国向制药强国跨越的背景下,中国百强制药企业石家庄四药集团(简称“石家庄四药”)大力实施“原料药+制剂”发展战略,通过资本合作、收购、重组的合作方式,积极拓展上下游产业链,增强国内外市场竞争力,为加快推进原料药业务板块布局发展再添新动力,一系列“大动作”正在使石家庄四药集团向原料药强企发展的目标前进。
See more information
石家庄四药集团广祥制药、国龙制药两产品获评省制造业单项冠军产品
2022-12-31

石家庄四药集团广祥制药、国龙制药两产品获评省制造业单项冠军产品

日前,河北省工信厅公布了第四批省制造业单项冠军企业和单项冠军产品名单,石家庄四药集团所属河北广祥制药有限公司甲硝唑、河北国龙制药有限公司羟乙基淀粉双双被认定为河北省制造业单项冠军产品。
See more
石家庄四药集团广祥制药被认定为省技术创新示范企业
2023-01-07

石家庄四药集团广祥制药被认定为省技术创新示范企业

1月6日,河北省工信厅公布2022年度省技术创新示范企业名单。集团河北广祥制药有限公司等36家企业被省工信厅认定为2022年度省技术创新示范企业。
See more
集团广祥制药获评2022年度河北省“职业健康企业”称号
2023-02-10

集团广祥制药获评2022年度河北省“职业健康企业”称号

日前,河北省卫生健康委员会、省工业和信息化厅、省生态环境厅、省总工会、共青团河北省委、省妇联六部门联合发布了2022年度河北省“职业健康企业”名单,集团河北广祥制药有限公司成功入围,获评省“职业健康企业”称号。
See more
石家庄四药集团阿加曲班原料药获批
2022-09-07

石家庄四药集团阿加曲班原料药获批

近日,石家庄四药集团河北广祥制药有限公司申报的阿加曲班获国家药品监督管理局批准登记为上市制剂使用的原料药。
See more

To promote the cause of human health with strength from China

SERVICE HOTLINE

SERVICE HOTLINE

+86-311-67167140

Zip Code: 052165
Address: No.9 Xingye Street, Gaocheng District, Shijiazhuang City, Hebei Province